

## **REMARKS**

### Amendments to the Claims

Claims 1-6 have been cancelled without prejudice or disclaimer.

New claims 7-11 have been added. The new claims are fully supported by Applicants' original specification and claims. New claim 7 is directed to a medium comprising the basal medium of claim 3 and the additional components or factors set forth in claim 5.

No new matter has been introduced by the addition of the new claims.

### Response to Restriction Requirement

In the Office Action dated July 27, 2010, the Examiner has required restriction between: Group I, namely Claims 1 & 4/1; Group II, namely Claims 2 & 4/2; Group III, namely Claims 3 & 4/3; Group IV, namely Claims 5/4/1; Group V, namely claims 5/4/2; Group VI, namely Claims 5/4/3; Group VII; namely Claims 6/5/4/1; Group VIII, namely Claims 6/5/4/2; and Group IX, namely Claims 6/5/4/3. Applicants hereby provisionally elect with traverse to prosecute the claims of Group VI (Claims 5/4/3) and expressly reserve the right to file divisional applications or take such other appropriate measures deemed necessary to protect the inventions in the remaining claims.

Responsive to the Restriction Requirement, Applicants have cancelled claims 1-6 and added new claims 7-11. New claims 7-10, are directed to the ES cell culture medium of Group VI and claim 11 is directed to culturing ES cells comprising culturing ES cells with the ES cell culture medium of Group VI. Thus, the subject matter of new claims 7-11 relates to a single general inventive concept under PCT Rule 13.1 because new claims 7-11 are directed to subject matter that is drawn to the same or corresponding technical feature in compliance with PCT Rule 13.2. Thus, the amended application meets the unity of invention requirement. Accordingly, Applicants respectfully request the Examiner to examine claims 7-11 in the instant application.

Should the Examiner have further questions or comments with respect to examination of this case, it is respectfully requested that the Examiner telephone the undersigned so that further examination of this application can be expedited.

It is not believed that extensions of time or fees for net addition of claims are required, beyond those, which may otherwise be provided for in documents accompanying this paper. However, in the event that additional extensions of time are necessary to allow consideration of this paper, such extensions are hereby petitioned under 37 C.F.R. § 1.136(a), and any fee required therefore (including fees for net addition of claims) is hereby authorized to be charged to Deposit Account No. 16-0605.

Respectfully submitted,

/david m. saravitz/

David M. Saravitz  
Registration No. 55,593

**CUSTOMER NO. 00826**  
**ALSTON & BIRD LLP**  
Bank of America Plaza  
101 South Tryon Street, Suite 4000  
Charlotte, NC 28280-4000  
Tel Raleigh Office (919) 862-2200  
Fax Raleigh Office (919) 862-2260

**ELECTRONICALLY FILED USING THE EFS-WEB ELECTRONIC FILING SYSTEM OF THE UNITED STATES PATENT & TRADEMARK OFFICE ON AUGUST 24, 2010.**